This Week in Obstetrics & Gynecology — Sep 10, 2026

Welcome to This Week in Obstetrics and Gynecology. This week we're covering 10 notable papers spanning a major change in how we name and frame polycystic ovary syndrome, pregnancy as a window into lifelong cardiovascular risk, and a cluster of practical papers in gynecologic oncology and delivery-room decision making. Let's dive in.

We start with a change in nomenclature that has real clinical consequences. In a Special Report in the American Journal of Obstetrics and Gynecology, Bahri-Khomami and colleagues explain that polycystic ovary syndrome has been formally renamed polyendocrine metabolic ovarian syndrome, following an international consensus process endorsed by 56 professional and patient organisations [1]. The argument is that the old name was simply wrong — the ovarian appearance reflects arrested antral follicles rather than pathological cysts — and that it anchored both clinicians and patients in an ovary-and-fertility framing of what is actually a lifelong endocrine and metabolic condition affecting roughly one in ten reproductive-aged women. The diagnostic criteria have not changed: still two of three from irregular cycles with ovulatory dysfunction, clinical or biochemical hyperandrogenism, and either elevated anti-Müllerian hormone or multiple follicles on ovarian ultrasound in adults. What changes is the clinical frame, and the authors make a specific, actionable point for obstetric practice — the condition is linked to higher risks of miscarriage, gestational diabetes, hypertensive disorders, caesarean delivery, preterm birth and growth restriction, with many of those associations persisting after adjustment for age and body mass index, and yet it is rarely captured as a risk modifier at the first obstetric visit. Pairing with that, a narrative review in Fertility and Sterility by HogenEsch and Huddleston follows the same condition past the reproductive years [10]. Their key message is that the reproductive phenotype softens with age — cycles regularise, ovulatory function and biochemical hyperandrogenism improve — but this is not remission. The metabolic dysfunction, the cardiovascular risk and the psychological burden persist into midlife and beyond, and the softening phenotype makes diagnosis in the thirties and forties genuinely harder. The practical implication across both papers is the same: document the diagnosis, carry it forward, and screen for cardiometabolic and psychological risk rather than closing the file once fertility is addressed.

That thread runs directly into a three-part Series in The Lancet on cardiovascular disease and pregnancy. The opening paper, from Brazile and colleagues, sets out the haemodynamic changes of pregnancy, the global burden of congenital and acquired heart disease entering pregnancy, and the performance of existing risk-stratification tools, with cardiovascular disease still among the leading causes of maternal death worldwide and still under-recognised and variably managed across settings [2]. The final paper in the Series, led by Pabón, is the one most likely to change what you write in a discharge summary [3]. It frames pregnancy as a physiological stress test that unmasks latent susceptibility, and synthesises the evidence that hypertensive disorders of pregnancy, gestational diabetes and preterm birth all mark women out for substantially higher long-term cardiovascular morbidity and mortality. The authors are candid about what we don't have: no adverse-pregnancy-outcome-specific prevention trials, uncertainty about the optimal follow-up model, and risk calculators that were never built with these variables in mind. Their proposal is to treat an adverse pregnancy outcome as an early, sex-specific risk indicator and hand it deliberately to primary care, rather than letting it evaporate at the six-week visit. Read alongside the polyendocrine metabolic ovarian syndrome papers, there's a consistent theme this week — obstetric events are not episodes, they're data about the next forty years.

Turning to the delivery room, Obstetrics and Gynecology published a secondary analysis by Doyle and colleagues of the Maternal-Fetal Medicine Units APEX cohort, examining episiotomy and anal sphincter injury during operative vaginal delivery in a modern United States population [4]. Among more than five thousand operative vaginal deliveries at term, about a third involved an episiotomy, and the vast majority of those were midline. Sphincter injury occurred in about one in five deliveries overall — a sobering baseline. After adjustment for second-stage duration, maternal age, body mass index and birthweight, episiotomy as a whole raised the odds of sphincter injury by roughly 45 percent, but the interaction analysis is where the clinical message sits. Midline episiotomy during vacuum-assisted delivery was associated with higher odds of sphincter injury regardless of whether the patient had delivered vaginally before. Mediolateral episiotomy, by contrast, was associated with lower odds of injury in patients without a prior vaginal delivery, for both vacuum and forceps. Given how heavily United States practice favours midline, that's a meaningful signal, and it aligns with work from settings with very different baseline rates. This is observational and the authors are appropriately cautious about identifying who actually benefits, but if you are performing an operative vaginal delivery in a nulliparous patient and you have decided an episiotomy is needed, the angle of that cut matters.

Three papers in gynecologic oncology round out the week. In Gynecologic Oncology, Deng and colleagues report a propensity-score-matched single-centre cohort of nearly eighteen hundred women with early-stage cervical cancer, comparing minimally invasive radical hysterectomy performed without a uterine manipulator, using protective vaginal transection, against open surgery [5]. After matching, disease-free and overall survival did not differ significantly between the two approaches, while the minimally invasive arm had markedly lower blood loss — a median of 100 millilitres versus 300 — far fewer intraoperative transfusions, faster return of bowel function and a day shorter in hospital, at the cost of longer operative time. Before anyone reverses course after the LACC trial, note the authors' own framing: follow-up after minimally invasive surgery was substantially shorter, there were only seventeen deaths in total, and that combination cannot support a claim of equivalence or non-inferiority. This is hypothesis-generating support for the manipulator-free technique, not a licence. Also in Gynecologic Oncology, Raffone and colleagues pooled nine studies covering 295 women having fertility-sparing treatment for early-stage endometrioid endometrial carcinoma, stratified by molecular group [6]. Complete response was around 95 percent in POLE-mutated tumours and about 82 percent in the no-specific-molecular-profile group, but fell to roughly 62 percent with mismatch repair deficiency and only about 41 percent in p53-abnormal disease — where nearly four in ten patients had progressive disease. Recurrence, it's worth noting, was common across every group. The numbers in the POLE and p53 strata are small, but if these hold, molecular classification belongs in the pre-treatment conversation about whether conservative management is realistic at all. And in the American Journal of Obstetrics and Gynecology, Krog and colleagues report a Danish nationwide cohort of 800 women treated with curative intent for vulvar squamous cell carcinoma [9]. Recurrence reached about one in five by two years and 35 percent by ten years, with isolated local recurrences continuing at a fairly constant rate for up to nine years after treatment. Five-year survival was about 73 percent after primary diagnosis but dropped to roughly 38 percent after a first recurrence — though notably to about 50 percent when that recurrence was isolated and local. Nearly 95 percent of patients with a local, locoregional or regional recurrence had a preceding symptom, most often itching with vulvar pain locally, or a groin lump with groin pain regionally. That argues strongly for structured symptom education rather than relying on surveillance visits alone.

Two review papers close out the week with immediately usable guidance. In the American Journal of Obstetrics and Gynecology, Balshi and colleagues update expert recommendations on multiple sclerosis across the reproductive years [7]. The overall message is reassuring — in most cases multiple sclerosis is not associated with major adverse pregnancy outcomes, though some studies show modestly higher rates of lower birthweight, preterm birth and operative delivery — and disease activity can usually be controlled by continuing or strategically timing disease-modifying therapy rather than reflexively stopping it. They flag the postpartum period as one of heightened medical and psychological risk warranting close follow-up, and remind us that after childbearing, gynecologic care shifts to therapy-associated infection risk, cervical dysplasia surveillance and the menopausal transition. And in Obstetrics and Gynecology, Negris and colleagues offer a morphology-driven framework for distinguishing genitourinary syndrome of menopause from vulvar dermatoses [8] — because dryness, dyspareunia and irritation are the common final pathway for lichen sclerosus, inflammatory and neoplastic conditions alike, and reflexively labelling everything as genitourinary syndrome of menopause delays biopsy and targeted treatment.

If you only have time for one paper this week, make it the episiotomy analysis in Obstetrics and Gynecology [4]. It addresses a decision you make under time pressure with a scalpel in your hand, in a population where sphincter injury affects one in five operative vaginal deliveries, and it challenges the default midline approach that dominates United States practice.

Here are the key takeaways from this week in Obstetrics and Gynecology. Polycystic ovary syndrome is now polyendocrine metabolic ovarian syndrome; the criteria are unchanged, but start documenting it as an obstetric risk modifier at booking and keep screening cardiometabolic and psychological risk well past menopause. Treat hypertensive disorders, gestational diabetes and preterm birth as durable cardiovascular risk markers and hand that information explicitly to whoever provides long-term care. During operative vaginal delivery, if an episiotomy is needed in a patient without a prior vaginal delivery, the evidence favours mediolateral over midline. In vulvar cancer, most recurrences are locally recurrent, symptomatic and spread out over nearly a decade, so patient symptom education is a genuine surveillance tool. And before offering fertility-sparing treatment for endometrial carcinoma, molecular classification may tell you whether success is likely — particularly the poor outlook with p53-abnormal disease.

That's your roundup for This Week in Obstetrics and Gynecology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.